Trial · NCT07387367
A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT
NCT07387367, Phase 3, Recruiting, SymBio Pharmaceuticals
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT. Trials, record NCT07387367. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07387367
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT
- NCT number
- NCT07387367
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 180 participants, estimated
- Lead sponsor
- SymBio Pharmaceuticals
- Conditions
- Adenovirus Infections
- Interventions
- cidofovir, Brincidofovir
- First posted
- 2026-02-04
- Last updated
- 2026-10-19
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | To assess efficacy of intravenous (IV) brincidofovir (BCV), compared with IV cidofovir (CDV), in subjects after allo-HCT with adenovirus (AdV) viremia. | Week (W) 5 Day (D) 1. | The primary efficacy endpoint is defined as AdV virological success at W5D1. -Proportion of subjects with AdV virological success |
| Secondary | To assess the efficacy and safety of IV BCV, and IV CDV, in subjects after allo-HCT with AdV viremia. | Test Of Cure (Last Dose + 30 days) | The proportion of subjects with overall success, as adjuducated by the EAC |
| Secondary | To assess the efficacy and safety of IV BCV, and IV CDV, in subjects after allo-HCT with AdV viremia. | Week 1 Day 1 Through End Of Study (Week 24). | Incidence and severity of treatment-emergent adverse events (TEAEs). |
| Secondary | To assess the efficacy and safety of IV BCV, and IV CDV, in subjects after allo-HCT with AdV viremia. | Week 5 Day 1, Last Dose + 4 Days, Last Dose + 30 days, Week 12, and Week 24. | All cause mortality |
| Secondary | BCV Plasma Concentrations will be collected, measured and reported | Plasma samples will be collected at Week 1 Day 1, and Week 5 Day 1 | The drug level (BCV) in plasma will be measured and used to examine the variability in drug concentrations among patients within the study population (i.e., population pharmacokinetics analysis). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07387367
GET https://conductscience.org/api/trials/v1/NCT07387367/registered